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Research Letter
Dear Editor,
The effectiveness of combination therapy with 308-nm excimer laser in vitiligo in Han Chinese People
Vitiligo is an acquired pigmentary disorder characterized by white macules that result from a loss of functioning melanocytes. 1 Currently various therapeutic modalities are available for the treatment of vitiligo, but these are reported to have limited efficacy with a relatively high occurrence of adverse events. There remains a demand for new therapies. 2, 3 Recently, 308-nm excimer laser has been reported to promote the proliferation and migration of melanocytes when used as an adjunt vitiligo treatment. [4] [5] [6] An advantage of 308-nm excimer laser over ultraviolet light, is the reduced risk of carcinogenesis. [7] [8] [9] We compare the efficiency of 308-nm excimer laser with combined therapy in vitiligo in Han Chinese adults. Patients seeking treatment for vitiligo (June 2016-2017) were approached for enrollment in the study. Eligible patients were 30-60 years old, with a body surface area involvement of <20%. Any concomitant treatment for vitiligo was restricted for 4 weeks before this study commenced. This study was approved by committee of our hospital. A total of 152 patients were randomly divided into three treatment groups: tacrolimus group: lesions of vitiligo received excimer laser twice per week with combination of 0.1% tacrolimus ointment twice daily; halometasone group: vitiligo lesions received excimer laser twice per week with combination of halometasone cream twice daily; excimer laser only group: vitiligo lesions received excimer laser twice per week only. Demographic features between these three groups were matched (Table 1) .
Once a subject's minimal erythema dose (MED) was determined, the target lesions were irradiated every 72 h for 12 weeks. The initial radiation dose was adjusted according to the extent of the erythema after the previous treatment. If the erythema lasted for 24-48 h, the dose remained the same; if it lasted <24 h, the dose was increased by 25-50 mJ/cm 2 ; if it lasted for 48-60 h, the dose was reduced 25-50 mJ/m 2 ; if the patient reported erythema and blisters, irradiation was suspend until resolution of symptoms and the dose was reduced 100mJ/m2 in next treatment. The treatment efficacies for all subjects were evaluated by a dermatologist blinded to treatment allocation after 6 and 12 weeks. Treatment efficacy was assessed using a visual grading system: no or weak effect, 0-25% repigmentation; moderate effect, >25-50% repigmentation; excellent effect, >50-99% repigmentation; and complete effect, 100% repigmentation. The data were analyzed by software SPSS 16.0. Data were described by percentage and Chi-square. In all tests, P < 0.05 was considered as the significance level.
All patients completed the 12-week treatment period (Table 2 and 3 ). The effective rates of repigmentation on face and neck, and trunk were higher than limb and acral (v 2 = 6.952, P = 0.008 face and neck vs. limb; v 2 = 11.284, P = 0.001 face and neck vs. acral; v 2 = 6.496, P = 0.011 trunk vs. limb; v 2 = 10.794, P = 0.001 trunk vs. acral). There was no significant difference between face and neck lesions and trunk lesions. The effective rates of repigmentation in the two combined therapy groups were both higher than 308-nm excimer laser only treatment (v 2 = 11.749, P = 0.001 tacrolimus + laser vs. laser only; v 2 = 21.356, P < 0.001 halometasone + laser vs. laser only).
Our study shows that patients with vitiligo who received combined treatment with halometasone and excimer laser had more satisfactory repigmentation in comparison with individuals who only underwent 308-nm excimer laser therapy, even little higher than the patients who received combined treatment with tacrolimus and excimer laser therapy, especially on face and neck and trunk sites. No or weak effect, 0-25% repigmentation; good effect, >25-50% repigmentation; excellent effect, >50 $ 99% repigmentation; complete effect, 100% repigmentation. Effective rates% = (the lesions of complete effect + the lesions of excellent effect)/all lesions 9 100%. No or weak effect, 0-25% repigmentation; good effect, >25-50% repigmentation; excellent effect, >50 $ 99% repigmentation; complete effect, 100% repigmentation. Effective rates% = (the lesions of complete effect + the lesions of excellent effect)/all lesions 9 100%.
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